Gilead 9-Month Sales Driven By Vistide
Gilead Sciences has reported total revenues of $30.1 million for thefirst nine months of 1997, a rise of 9% on the corresponding period last year, with a net loss of $15.6 million, an increase of 14.7%. Net loss for the third quarter was $10.3 million.
Revenues were derived from sales of Vistide (cidofovir injection) for the treatment of cytomegalovirus retinitis in patients with AIDS, and include both US and European sales, it being the first quarter that Gilead has received royalties from Pharmacia & Upjohn for sales of Vistide in Europe. Gilead noted that it was profitable in the comparable third quarter, 1996, because of two non-recurring fees under agreements with P&U and Hoffmann-La Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze